

Lu Si

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3412486/publications.pdf>

Version: 2024-02-01

154
papers

2,845
citations

218381

26
h-index

214527

47
g-index

160
all docs

160
docs citations

160
times ranked

3484
citing authors

#	ARTICLE	IF	CITATIONS
1	EZH2 Inhibitor Enhances the STING Agonist-Induced Antitumor Immunity in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1158-1170.e8.	0.3	14
2	Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study*. <i>British Journal of Dermatology</i> , 2022, 186, 977-987.	1.4	9
3	The efficacy of 99mTc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients. <i>Annals of Translational Medicine</i> , 2022, 10, 95-95.	0.7	1
4	Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 341-341.	0.8	0
5	Clinical characteristics of patients with collecting duct carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 297-297.	0.8	0
6	Prognostic value of HER2 expression levels for upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 557-557.	0.8	5
7	Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 515-515.	0.8	24
8	Impact of different HER2 expression levels on the outcomes of second-line immunotherapy for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 524-524.	0.8	1
9	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
10	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
11	Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 354-362.	0.9	4
12	OrienX010, an oncolytic virus, in patients with unresectable stage III-IV melanoma: a phase Ib study. , 2022, 10, e004307.		13
13	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. <i>Annals of Surgical Oncology</i> , 2022, 29, 5221-5234.	0.7	15
14	Evolving Treatment Approaches to Mucosal Melanoma. <i>Current Oncology Reports</i> , 2022, 24, 1261-1271.	1.8	7
15	ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
16	The association of Ki67 level and adjuvant treatment options in mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21582-e21582.	0.8	0
17	Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9525-9525.	0.8	1
18	Phase Ib study of anlotinib in combination with anti-PD-L1 ab (TQB2450) in patients with advanced acral melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21543-e21543.	0.8	0

#	ARTICLE	IF	CITATIONS
19	A phase Ia/Ib study evaluating the safety and efficacy of intratumorally administrated OH2, an oncolytic herpes simplex virus 2, in unresected stage IIIC to IV melanoma patients.. Journal of Clinical Oncology, 2022, 40, e21537-e21537.	0.8	1
20	Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase 1b clinical trial of anti-PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage III melanoma with liver metastases.. Journal of Clinical Oncology, 2022, 40, 9551-9551.	0.8	2
21	A phase I dose-escalation study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma and other solid tumors.. Journal of Clinical Oncology, 2022, 40, e14586-e14586.	0.8	0
22	A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).. Journal of Clinical Oncology, 2022, 40, 9508-9508.	0.8	5
23	Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial.. Journal of Clinical Oncology, 2022, 40, 9578-9578.	0.8	2
24	Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase I, open-label, multicenter, dose escalation/expansion study.. Journal of Clinical Oncology, 2022, 40, 9538-9538.	0.8	2
25	Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.. Journal of Clinical Oncology, 2022, 40, 9512-9512.	0.8	2
26	Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 75.e1-75.e8.	0.8	9
27	Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Translational Oncology, 2021, 14, 100949.	1.7	6
28	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2021, 27, 43-51.	3.2	125
29	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. Npj Genomic Medicine, 2021, 6, 7.	1.7	41
30	Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2731-2740.	1.2	3
31	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		7
32	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology, 2021, 39, 881-889.	0.8	37
33	Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.. Journal of Clinical Oncology, 2021, 39, 9539-9539.	0.8	2
34	Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy: Ad hoc Analyses of Pooled Data From Two Clinical Trials. Frontiers in Oncology, 2021, 11, 639085.	1.3	6
35	Clinicopathologic features of Xp11.2 translocation renal cell carcinoma and its response to target therapy.. Journal of Clinical Oncology, 2021, 39, e16559-e16559.	0.8	0
36	A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma.. Journal of Clinical Oncology, 2021, 39, 9512-9512.	0.8	9

#	ARTICLE	IF	CITATIONS
37	A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma.. Journal of Clinical Oncology, 2021, 39, 9570-9570.	0.8	5
38	Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.. Journal of Clinical Oncology, 2021, 39, 9511-9511.	0.8	5
39	Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. European Journal of Cancer, 2021, 148, 297-306.	1.3	19
40	Genetic alteration of Chinese patients with rectal mucosal melanoma. BMC Cancer, 2021, 21, 623.	1.1	2
41	RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.. Journal of Clinical Oncology, 2021, 39, 4534-4534.	0.8	10
42	Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN- α 2b in resected mucosal melanoma: A phase randomized trial.. Journal of Clinical Oncology, 2021, 39, 9573-9573.	0.8	4
43	Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).. Journal of Clinical Oncology, 2021, 39, 9530-9530.	0.8	1
44	Second-line (2L) pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Three-year follow up (FU) of the phase 1 KEYNOTE-151 study.. Journal of Clinical Oncology, 2021, 39, e21511-e21511.	0.8	0
45	Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Frontiers in Immunology, 2021, 12, 680407.	2.2	68
46	Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Frontiers in Immunology, 2021, 12, 691032.	2.2	10
47	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clinical Cancer Research, 2021, 27, 5993-6000.	3.2	70
48	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Frontiers in Oncology, 2021, 11, 720044.	1.3	9
49	Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. European Journal of Cancer, 2021, 156, 83-92.	1.3	7
50	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. Frontiers in Pharmacology, 2021, 12, 747416.	1.6	0
51	Surgical Outcomes of Vaginal or Cervical Melanoma. Frontiers in Surgery, 2021, 8, 771160.	0.6	1
52	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Frontiers in Oncology, 2020, 10, 546604.	1.3	15
53	Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma. Frontiers in Oncology, 2020, 10, 1524.	1.3	24
54	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. European Journal of Cancer, 2020, 135, 31-38.	1.3	11

#	ARTICLE	IF	CITATIONS
55	ASO Author Reflections: Primary Site Should Be Regarded as One Important Factor for Risk Stratification in Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3486-3487.	0.7	0
56	Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. <i>EBioMedicine</i> , 2020, 55, 102755.	2.7	12
57	The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3478-3485.	0.7	29
58	A Functional Synonymous Variant in <i>PDGFRA</i> Is Associated with Better Survival in Acral Melanoma. <i>Journal of Cancer</i> , 2020, 11, 2945-2956.	1.2	8
59	A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 10040-10040.	0.8	10
60	A first-in-human phase I/II study of HL-085, a MEK Inhibitor, in Chinese patients with NRASm advanced melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 10047-10047.	0.8	5
61	A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, e17113-e17113.	0.8	9
62	Phase II study of apatinib combined with temozolomide in advanced melanoma patients after failure of anti-PD-1 therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, e22043-e22043.	0.8	1
63	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6511-6523.	3.2	62
64	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G ₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2987-2999.	0.8	126
65	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	5.8	205
66	Identification of a functional polymorphism within the 3' untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma. <i>European Journal of Cancer</i> , 2019, 118, 70-81.	1.3	13
67	Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing. <i>Journal of Cancer</i> , 2019, 10, 488-493.	1.2	8
68	miR-let-7b and miR-let-7c suppress tumorigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 212.	3.5	53
69	RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 254.	2.7	40
70	Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. <i>Thoracic Cancer</i> , 2019, 10, 950-956.	0.8	27
71	MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways. <i>Theranostics</i> , 2019, 9, 945-960.	4.6	49
72	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). <i>Translational Oncology</i> , 2019, 12, 828-835.	1.7	90

#	ARTICLE	IF	CITATIONS
73	Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study. <i>Oncology Research</i> , 2019, 27, 495-501.	0.6	26
74	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 7.	6.9	113
75	Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9528-9528.	0.8	7
76	Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21050-e21050.	0.8	2
77	A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9521-9521.	0.8	1
78	A clinical prognosis model for Asian advanced melanoma patients receiving immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14081-e14081.	0.8	0
79	Mucosal melanoma staging and classification: Firstly established.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21008-e21008.	0.8	0
80	Mucosal melanoma of the female genital tract: Operation modalities.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21060-e21060.	0.8	1
81	Postoperative radiotherapy in resected sinonasal mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21059-e21059.	0.8	0
82	Continuous intravenous infusion Rh-endostatin in combination with dacarbazine and cisplatin as the first-line therapy for metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21007-e21007.	0.8	0
83	Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma. <i>Human Pathology</i> , 2018, 75, 137-145.	1.1	10
84	Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. <i>Annals of Surgical Oncology</i> , 2018, 25, 885-893.	0.7	7
85	PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro. <i>Cancer Biology and Therapy</i> , 2018, 19, 584-589.	1.5	30
86	Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. <i>European Journal of Cancer</i> , 2018, 89, 90-101.	1.3	19
87	Analysis of TSC1 mutation spectrum in mucosal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 257-267.	1.2	12
88	High G2 and S&Ephase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis. <i>Cancer Science</i> , 2018, 109, 1787-1798.	1.7	19
89	Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. <i>European Journal of Cancer</i> , 2018, 100, 1-7.	1.3	31
90	Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. <i>Translational Oncology</i> , 2018, 11, 1155-1159.	1.7	8

#	ARTICLE	IF	CITATIONS
91	<i>TERT</i> copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4097-4104.	1.0	28
92	Increased <i>AURKA</i> Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma. <i>Journal of Cancer</i> , 2018, 9, 1267-1276.	1.2	7
93	Vemurafenib in Chinese patients with BRAFV600 mutationâ€“positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. <i>BMC Cancer</i> , 2018, 18, 520.	1.1	10
94	Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. <i>Journal of Hematology and Oncology</i> , 2018, 11, 1.	6.9	196
95	Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2018, 25, 2184-2192.	0.7	34
96	A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9528-9528.	0.8	9
97	A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9539-9539.	0.8	12
98	Phase â…¢ randomized, multicenter trial comparing high-dose IFN-â2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9589-9589.	0.8	18
99	Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16505-e16505.	0.8	3
100	Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report. <i>Chinese Clinical Oncology</i> , 2018, 7, 62-62.	0.4	16
101	Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma. <i>Scientific Reports</i> , 2017, 7, 39597.	1.6	10
102	Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6946-6957.	3.2	73
103	Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. <i>Oncology Letters</i> , 2017, 14, 3601-3605.	0.8	25
104	<i>MAPK</i> Pathway and <i>TERT</i> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 6120-6127.	3.2	71
105	Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. <i>Translational Oncology</i> , 2017, 10, 719-725.	1.7	27
106	Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. <i>Oncology Letters</i> , 2017, 15, 1839-1844.	0.8	12
107	A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4575-4575.	0.8	5
108	Immunotherapy of patients with metastatic melanoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 20-20.	0.4	13

#	ARTICLE	IF	CITATIONS
109	Multivariate analysis of prognostic factors among 706 mucosal melanoma patients.. Journal of Clinical Oncology, 2017, 35, 9569-9569.	0.8	0
110	Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.. Journal of Clinical Oncology, 2017, 35, e21017-e21017.	0.8	4
111	OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment.. Journal of Clinical Oncology, 2017, 35, e21013-e21013.	0.8	4
112	Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget, 2016, 7, 27044-27054.	0.8	28
113	Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials. Cancer Medicine, 2016, 5, 17-23.	1.3	14
114	GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. European Journal of Cancer, 2016, 65, 156-163.	1.3	55
115	Analysis of <i>mTOR</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. Clinical Cancer Research, 2016, 22, 1018-1027.	3.2	69
116	OrienX010 oncolytic viral therapy in phase A b trial of intralesional injection in unresected stage A c to A e acral melanoma patients in China.. Journal of Clinical Oncology, 2016, 34, e21001-e21001.	0.8	2
117	Association of immune-inflammation index with outcome of high-risk acral melanoma patients treated with adjuvant high-dose interferon.. Journal of Clinical Oncology, 2016, 34, e21070-e21070.	0.8	4
118	Imatinib versus interferon as adjuvant therapy in a phase II study in patients with highrisk C-Kit mutated melanoma.. Journal of Clinical Oncology, 2016, 34, e21073-e21073.	0.8	1
119	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chinese Clinical Oncology, 2016, 5, 57-57.	0.4	46
120	The expression and clinical significance of PD-L1 in patients with upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2016, 34, 444-444.	0.8	0
121	A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).. Journal of Clinical Oncology, 2016, 34, e21043-e21043.	0.8	0
122	Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy.. Journal of Clinical Oncology, 2016, 34, 9512-9512.	0.8	0
123	A prospective multicenter phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma (NCT01762150).. Journal of Clinical Oncology, 2016, 34, 4559-4559.	0.8	0
124	Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. British Journal of Ophthalmology, 2015, 99, 990-996.	2.1	46
125	Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations.. Journal of Clinical Oncology, 2015, 33, 9047-9047.	0.8	5
126	Preliminary results of a phase II trial with continuous intravenous infusion of rh-endostatin in combination with dacarbazine as the first-line therapy for metastatic acral melanoma.. Journal of Clinical Oncology, 2015, 33, e20087-e20087.	0.8	1

#	ARTICLE	IF	CITATIONS
127	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Annals of Translational Medicine</i> , 2015, 3, 322.	0.7	32
128	Genetic polymorphisms of PDGFR/VEGFR2/VEGFR3/RET and their relevance to thrombocytopenia in mRCC patients treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 481-481.	0.8	0
129	A phase II study of everolimus for advanced melanoma patients with mTOR mutations.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20007-e20007.	0.8	0
130	The efficacy and safety analysis of sunitinib plus temozolomide therapy in patients with metastatic mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20043-e20043.	0.8	0
131	Effect of nanosecond pulsed electric fields in combination with everolimus on melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20102-e20102.	0.8	0
132	Clinical presentation, systemic therapy and prognosis of mucosal melanoma, a study of 463 consecutive cases.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20036-e20036.	0.8	0
133	Analysis of mTOR Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9049-9049.	0.8	0
134	A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15591-e15591.	0.8	0
135	A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20076-e20076.	0.8	0
136	Comparison of clinical presentation and prognosis between acral cutaneous melanoma and non-acral cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20008-e20008.	0.8	0
137	Genotyping of mucosal melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 34.	0.4	14
138	Treatment algorithm of metastatic mucosal melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 38.	0.4	16
139	Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15556-e15556.	0.8	0
140	Outcome of isolated limb infusion (ILI) treatment for Chinese acral melanoma patients with/without gene mutations.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20014-e20014.	0.8	0
141	Primary malignant melanoma of the esophagus: Clinical features, signaling pathway, management, and survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20015-e20015.	0.8	0
142	Effect of restoration of microRNA-18a on improvement of imatinib therapy on secondary imatinib-resistance metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9040-9040.	0.8	0
143	Salvage therapy for metastatic acral or mucosal melanoma: Efficacy and safety analysis of nab-paclitaxel/carboplatin combined with bevacizumab in c-kit/BRAF wild-type pts.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20017-e20017.	0.8	0
144	A pilot, open-label phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15554-e15554.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Prognostic factors for disease-free survival of ethnic Chinese patients with ocularmelanoma.. Journal of Clinical Oncology, 2014, 32, e20016-e20016.	0.8	0
146	C-kit-mutated melanomas. Current Opinion in Oncology, 2013, 25, 160-165.	1.1	15
147	A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.. Journal of Clinical Oncology, 2013, 31, e20027-e20027.	0.8	0
148	Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance. Journal of Clinical Oncology, 2012, 30, e37-e40.	0.8	23
149	Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. European Journal of Cancer, 2012, 48, 94-100.	1.3	199
150	Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma.. Journal of Clinical Oncology, 2012, 30, 8506-8506.	0.8	3
151	Association of the activation of the mTOR pathway with prognosis in Chinese melanoma patients.. Journal of Clinical Oncology, 2012, 30, 8561-8561.	0.8	0
152	mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance.. Journal of Clinical Oncology, 2012, 30, 8562-8562.	0.8	0
153	Primary hypertension to predict progression-free survival of target therapy in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e15052-e15052.	0.8	1
154	Association of single nucleotide polymorphisms in AGT, VEGF, and APOE genes with clinical outcome of target therapy in advanced renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e15051-e15051.	0.8	1